Interferons at age 50: past, current and future impact on biomedicine
Identifieur interne : 003968 ( Main/Exploration ); précédent : 003967; suivant : 003969Interferons at age 50: past, current and future impact on biomedicine
Auteurs : Ernest C. Borden [États-Unis] ; Ganes C. Sen [États-Unis] ; Gilles Uze [France] ; Robert H. Silverman [États-Unis] ; Richard M. Ransohoff [États-Unis] ; Graham R. Foster [Royaume-Uni] ; George R. Stark [États-Unis]Source :
- Nature Reviews Drug Discovery [ 1474-1776 ] ; 2007-12.
Abstract
The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.
Url:
- https://api.istex.fr/ark:/67375/GT4-KRH340F0-4/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097588
DOI: 10.1038/nrd2422
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001F25
- to stream Istex, to step Curation: 001F25
- to stream Istex, to step Checkpoint: 001312
- to stream Pmc, to step Corpus: 000556
- to stream Pmc, to step Curation: 000556
- to stream Pmc, to step Checkpoint: 000F41
- to stream Ncbi, to step Merge: 001B29
- to stream Ncbi, to step Curation: 001B29
- to stream Ncbi, to step Checkpoint: 001B29
- to stream Main, to step Merge: 003B23
- to stream Main, to step Curation: 003968
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferons at age 50: past, current and future impact on biomedicine</title>
<author><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
</author>
<author><name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
</author>
<author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
</author>
<author><name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
</author>
<author><name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
</author>
<author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
</author>
<author><name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1038/nrd2422</idno>
<idno type="url">https://api.istex.fr/ark:/67375/GT4-KRH340F0-4/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F25</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001F25</idno>
<idno type="wicri:Area/Istex/Curation">001F25</idno>
<idno type="wicri:Area/Istex/Checkpoint">001312</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001312</idno>
<idno type="wicri:doubleKey">1474-1776:2007:Borden E:interferons:at:age</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097588</idno>
<idno type="RBID">PMC:7097588</idno>
<idno type="wicri:Area/Pmc/Corpus">000556</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000556</idno>
<idno type="wicri:Area/Pmc/Curation">000556</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000556</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000F41</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F41</idno>
<idno type="wicri:Area/Ncbi/Merge">001B29</idno>
<idno type="wicri:Area/Ncbi/Curation">001B29</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B29</idno>
<idno type="wicri:doubleKey">1474-1776:2007:Borden E:interferons:at:age</idno>
<idno type="wicri:Area/Main/Merge">003B23</idno>
<idno type="wicri:Area/Main/Curation">003968</idno>
<idno type="wicri:Area/Main/Exploration">003968</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Interferons at age 50: past, current and future impact on biomedicine</title>
<author><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>CNRS UMR 5235, Place Eugene Bataillon, Montpellier, Cedex 5 FR34095</wicri:regionArea>
<placeName><region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Languedoc-Roussillon</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Institute of Cell and Molecular Science, Queen Mary's School of Medicine, 4 Newark Street, London E1 4AT</wicri:regionArea>
<wicri:noRegion>London E1 4AT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">États-Unis</country>
<wicri:regionArea>Taussig Cancer Center, Case Comprehensive Cancer Center, Mellen Center for Multiple Sclerosis, and Lerner Research Institute, The Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195</wicri:regionArea>
<wicri:noRegion>Ohio 44195</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Nature Reviews Drug Discovery</title>
<idno type="ISSN">1474-1776</idno>
<idno type="eISSN">1474-1784</idno>
<imprint><publisher>Nature Publishing Group</publisher>
<date when="2007-12">2007-12</date>
<biblScope unit="vol">6</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="975">975</biblScope>
<biblScope unit="page" to="990">990</biblScope>
<date type="Copyright" when="2007">2007</date>
</imprint>
<idno type="ISSN">1474-1776</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1474-1776</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">The family of interferon (IFN) proteins has now more than reached the potential envisioned by early discovering virologists: IFNs are not only antivirals with a spectrum of clinical effectiveness against both RNA and DNA viruses, but are also the prototypic biological response modifiers for oncology, and show effectiveness in suppressing manifestations of multiple sclerosis. Studies of IFNs have resulted in fundamental insights into cellular signalling mechanisms, gene transcription and innate and acquired immunity. Further elucidation of the multitude of IFN-induced genes, as well as drug development strategies targeting IFN production via the activation of the Toll-like receptors (TLRs), will almost certainly lead to newer and more efficacious therapeutics. Our goal is to offer a molecular and clinical perspective that will enable IFNs or their TLR agonist inducers to reach their full clinical potential.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Languedoc-Roussillon</li>
<li>Occitanie (région administrative)</li>
</region>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Borden, Ernest C" sort="Borden, Ernest C" uniqKey="Borden E" first="Ernest C." last="Borden">Ernest C. Borden</name>
</noRegion>
<name sortKey="Ransohoff, Richard M" sort="Ransohoff, Richard M" uniqKey="Ransohoff R" first="Richard M." last="Ransohoff">Richard M. Ransohoff</name>
<name sortKey="Sen, Ganes C" sort="Sen, Ganes C" uniqKey="Sen G" first="Ganes C." last="Sen">Ganes C. Sen</name>
<name sortKey="Silverman, Robert H" sort="Silverman, Robert H" uniqKey="Silverman R" first="Robert H." last="Silverman">Robert H. Silverman</name>
<name sortKey="Stark, George R" sort="Stark, George R" uniqKey="Stark G" first="George R." last="Stark">George R. Stark</name>
</country>
<country name="France"><region name="Occitanie (région administrative)"><name sortKey="Uze, Gilles" sort="Uze, Gilles" uniqKey="Uze G" first="Gilles" last="Uze">Gilles Uze</name>
</region>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Foster, Graham R" sort="Foster, Graham R" uniqKey="Foster G" first="Graham R." last="Foster">Graham R. Foster</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003968 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003968 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E6F16A5249E7EBA21F2651DD0D3AB907DC275B6E |texte= Interferons at age 50: past, current and future impact on biomedicine }}
This area was generated with Dilib version V0.6.33. |